Ohm20 your understanding of this mechanism definitely exceeds mine. The (very) basic point for me is that Leronlimab blocks at the receptor site and preserves GPCR functioning, rather than functionally disabling through allosteric modulation.

I believe that is the huge advantage over maraviroc and the like. Thanks for the knowledge you bring to and share with this board.